Jill Weissberg-Benchell1, Jenna B Shapiro1, Fred B Bryant2, Korey K Hood3. 1. Pritzker Department of Psychiatry and Behavioral Health, Ann & Robert H. Lurie Children's Hospital of Chicago. 2. Department of Psychology, Loyola University Chicago. 3. Department of Pediatrics, Stanford University.
Abstract
OBJECTIVE: This article reports the 3-year outcomes for the Supporting Teen Problem-Solving (STePS) multisite Randomized Control Trial (RCT); reporting the overall impact of the STePS trial, and the differential impact of each arm of the trial (a resilience promoting intervention [PRP T1D] vs. a diabetes education intervention [EI]) on diabetes-specific emotional distress and depressive symptoms. METHOD:Participants included 264 adolescents with Type 1 diabetes (T1D), ages 14-18, in Chicago and San Francisco. Both intervention arms lasted 4.5 months and assessments were conducted at baseline, postintervention (4.5 months), and 5 follow-up visits (8, 12, 16, 28, and 40 months from baseline). Intervention efficacy was investigated using latent growth curve modeling (LGCM) to analyze the rate and shape of change of outcomes from preintervention across postintervention and follow-up time points. RESULTS:Mean age of participants was 15.7 years, mean T1D duration was 6.9 years, mean HbA1c at baseline was 9.1%. The sample was diverse with nearly 35% identifying as racial or ethnic minorities, and 60% were female. PRP T1D participants reported significantly lower diabetes distress compared with EI participants, and the effect size increased over time. For the pooled sample, while 40% of youth reported elevated distress at baseline, only 23% reported elevated distress 3 years postintervention. Moreover, PRP T1D participants experienced a significant decline in depressive symptoms from 16 to 40 months postbaseline, while participants in the education arm did not. CONCLUSIONS: Results from the 3-year outcomes assessment demonstrate the robust effects of PRP T1D in adolescents with declines in distress and depressive symptoms. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
RCT Entities:
OBJECTIVE: This article reports the 3-year outcomes for the Supporting Teen Problem-Solving (STePS) multisite Randomized Control Trial (RCT); reporting the overall impact of the STePS trial, and the differential impact of each arm of the trial (a resilience promoting intervention [PRP T1D] vs. a diabetes education intervention [EI]) on diabetes-specific emotional distress and depressive symptoms. METHOD:Participants included 264 adolescents with Type 1 diabetes (T1D), ages 14-18, in Chicago and San Francisco. Both intervention arms lasted 4.5 months and assessments were conducted at baseline, postintervention (4.5 months), and 5 follow-up visits (8, 12, 16, 28, and 40 months from baseline). Intervention efficacy was investigated using latent growth curve modeling (LGCM) to analyze the rate and shape of change of outcomes from preintervention across postintervention and follow-up time points. RESULTS: Mean age of participants was 15.7 years, mean T1D duration was 6.9 years, mean HbA1c at baseline was 9.1%. The sample was diverse with nearly 35% identifying as racial or ethnic minorities, and 60% were female. PRP T1D participants reported significantly lower diabetes distress compared with EI participants, and the effect size increased over time. For the pooled sample, while 40% of youth reported elevated distress at baseline, only 23% reported elevated distress 3 years postintervention. Moreover, PRP T1D participants experienced a significant decline in depressive symptoms from 16 to 40 months postbaseline, while participants in the education arm did not. CONCLUSIONS: Results from the 3-year outcomes assessment demonstrate the robust effects of PRP T1D in adolescents with declines in distress and depressive symptoms. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
Authors: Sarah D Corathers; Jessica Kichler; Nana-Hawa Yayah Jones; Andrea Houchen; Mary Jolly; Nancy Morwessel; Peggy Crawford; Lawrence M Dolan; Korey K Hood Journal: Pediatrics Date: 2013-10-14 Impact factor: 7.124
Authors: Anna S Serlachius; Shannon E Scratch; Elisabeth A Northam; Erica Frydenberg; Katherine J Lee; Fergus J Cameron Journal: J Health Psychol Date: 2014-09-10
Authors: Deborah A Ellis; April I Carcone; Richard Slatcher; Sylvie Naar-King; Anthony Hains; Amy Graham; Erica Sibinga Journal: Pediatr Diabetes Date: 2018-12-27 Impact factor: 4.866
Authors: Katherine J W Baucom; Tara L Queen; Deborah J Wiebe; Sara L Turner; Kristin L Wolfe; Elida I Godbey; Katherine T Fortenberry; Jessica H Mansfield; Cynthia A Berg Journal: Health Psychol Date: 2015-03-23 Impact factor: 4.267
Authors: Jenna B Shapiro; Anthony T Vesco; Lindsey E G Weil; Meredyth A Evans; Korey K Hood; Jill Weissberg-Benchell Journal: J Pediatr Psychol Date: 2018-06-01
Authors: Adam B Lewin; Annette M LaGreca; Gary R Geffken; Laura B Williams; Danny C Duke; Eric A Storch; Janet H Silverstein Journal: J Pediatr Psychol Date: 2009-05-07
Authors: Ryan M Hill; Katherine A S Gallagher; Sahar S Eshtehardi; Serife Uysal; Marisa E Hilliard Journal: Curr Diab Rep Date: 2021-12-13 Impact factor: 4.810
Authors: Jenna B Shapiro; Fred B Bryant; Grayson N Holmbeck; Korey K Hood; Jill Weissberg-Benchell Journal: Health Psychol Date: 2021-05 Impact factor: 4.267
Authors: Anthony T Vesco; Kelsey R Howard; Lindsay M Anderson; Jaclyn L Papadakis; Korey K Hood; Jill Weissberg-Benchell Journal: Can J Diabetes Date: 2021-05-11 Impact factor: 2.774